You are viewing a free summary from Descrybe.ai. For citation checking, legal issue analysis, and other advanced tools, explore our Legal Research Toolkit — not free, but close.

Haimowitz v. Novartis Pharmaceuticals Corp.

Citations: 148 F. Supp. 3d 327; 2015 U.S. Dist. LEXIS 166418; 2015 WL 8675349Docket: No. 09 Civ. 10068 (JFK)

Court: District Court, S.D. New York; December 10, 2015; Federal District Court

Narrative Opinion Summary

The case involves a dispute over the timeliness of tort and breach of warranty claims filed by the children of a deceased individual, who alleged that her bisphosphonate-related osteonecrosis of the jaw was caused by the drug Aredia, manufactured by Novartis Pharmaceuticals Corporation. The plaintiff, originally a New York resident who later moved to Maryland, filed the lawsuit in December 2009, asserting that Maryland law should apply to her claims. However, the court determined that New York law governed due to the forum state's requirements in cases of federal diversity jurisdiction. New York's three-year statute of limitations for latent injuries begins at the injury's discovery, and the plaintiff's symptoms were evident by August 2002, rendering the claims untimely. The court also rejected the plaintiff's reliance on the unknown cause exception, as it could not extend the statute sufficiently. Breach of warranty claims were similarly time-barred, accruing in 2002 and exceeding the four-year period by the time of filing. Consequently, Novartis's motion for summary judgment was granted, ruling in their favor on all claims.

Legal Issues Addressed

Borrowing Statute in Federal Diversity Jurisdiction

Application: The court applied New York's statute of limitations as it was the forum state, requiring timeliness under both New York and any other applicable state's law.

Reasoning: In cases of federal diversity jurisdiction, the district court must apply the forum state's statute of limitations. Since New York is the forum, its law applies.

Breach of Warranty Claims Accrual

Application: The court determined the plaintiff's breach of warranty claims were untimely under New York's four-year statute, accruing at the time of the last sale of Aredia in 2002.

Reasoning: Under New York law, breach of warranty claims accrue upon tender of delivery, typically at the time of the last sale of the product.

Statute of Limitations under New York Law

Application: The court found the plaintiff's tort claims untimely under New York's three-year statute of limitations for latent injuries, which begins upon discovery of the injury.

Reasoning: New York’s three-year statute of limitations for tort claims involving latent injuries commences upon the plaintiff's discovery of the injury, defined as awareness of the physical condition rather than its cause.

Summary Judgment Standard

Application: The court applied the standard requiring no genuine issue of material fact and entitlement to judgment as a matter of law, determining that Novartis met this burden by proving the statute of limitations had expired.

Reasoning: The legal standard for summary judgment requires that there be no genuine issue of material fact and that the movant is entitled to judgment as a matter of law.

Unknown Cause Exception to Statute of Limitations

Application: Plaintiff's reliance on the unknown cause exception was insufficient to toll the statute of limitations, as the claims accrued by August 2002 and were filed in December 2009.

Reasoning: Even assuming this exception applies, Haimowitz's tort claims are still time-barred, as they accrued by August 2002 and the action was not filed until December 2009—over seven years later.